Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00331_nanopub.RAk6BL8cWYPTRLogknNE80iauvMYjJ8kLqo4B7BTPqwlE#assertion>. }
Showing items 1 to 27 of
27
with 100 items per page.
- drugbank:DB00331 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00331 label "Metformin [drugbank:DB00331]" assertion.
- drugbank:DB00331 seeAlso DB00331 assertion.
- drugbank:DB00331 seeAlso metformin.html assertion.
- drugbank:DB00331 seeAlso glumetza.htm assertion.
- drugbank:DB00331 identifier "drugbank:DB00331" assertion.
- drugbank:DB00331 description "Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus (NIDDM). It improves glycemic control by decreasing hepatic glucose production, decreasing glucose absorption and increasing insulin-mediated glucose uptake. Metformin is the only oral antihyperglycemic agent that is not associated with weight gain. Metformin may induce weight loss and is the drug of choice for obese NIDDM patients. When used alone, metformin does not cause hypoglycemia; however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin. Its main side effects are dyspepsia, nausea and diarrhea. Dose titration and/or use of smaller divided doses may decrease side effects. Metformin should be avoided in those with severely compromised renal function (creatinine clearance < 30 ml/min), acute/decompensated heart failure, severe liver disease and for 48 hours after the use of iodinated contrast dyes due to the risk of lactic acidosis. Lower doses should be used in the elderly and those with decreased renal function. Metformin decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Metformin may also have a positive effect on lipid levels. In 2012, a combination tablet of linagliptin plus metformin hydrochloride was marketed under the name Jentadueto for use in patients when treatment with both linagliptin and metformin is appropriate." assertion.
- drugbank:DB00331 title "Metformin" assertion.
- drugbank:DB00331 bio2rdf_vocabulary:identifier "DB00331" assertion.
- drugbank:DB00331 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00331 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00331" assertion.
- drugbank:DB00331 bio2rdf_vocabulary:x-identifiers.org DB00331 assertion.
- drugbank:DB00331 drugbank_vocabulary:drugbank-id "APRD01099" assertion.
- drugbank:DB00331 drugbank_vocabulary:drugbank-id "DB00331" assertion.
- drugbank:DB00331 drugbank_vocabulary:x-cas cas:657-24-9 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-chemspider chemspider:3949 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-pubchemcompound pubchem.compound:4091 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46507752 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-ahfs ahfs:68:20.04 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-atc atc:A10BD11 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-chebi chebi:6801 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-dpd dpd:2265583 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-kegg kegg:C07151 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-kegg kegg:D04966 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-pharmgkb pharmgkb:PA450395 assertion.
- drugbank:DB00331 drugbank_vocabulary:x-wikipedia wikipedia:Metformin assertion.
- drugbank:DB00331 drugbank_vocabulary:x-ndc ndc:0781-5050-61 assertion.